No new guid­ance, but here's some ad­vice: FDA draws a line in the sand for Covid-19 vac­cine de­vel­op­ers

Less than a day af­ter re­ports emerged that the White House cit­ed in­dus­try op­po­si­tion in a move to block stricter Covid-19 vac­cine guide­lines, the FDA is spelling out ex­act­ly what reg­u­la­tors have been com­mu­ni­cat­ing to de­vel­op­ers look­ing for an emer­gency use au­tho­riza­tion.

In do­ing so, the reg­u­la­tors are of­fi­cial­ly draw­ing a line in the sand amid an in­creas­ing­ly chaot­ic cam­paign to bring a vac­cine to mar­ket at record speed.

In the brief­ing doc­u­ments for the Vac­cines and Re­lat­ed Bi­o­log­i­cal Prod­ucts Ad­vi­so­ry Com­mit­tee ahead of its Oct. 22, 2020 meet­ing, the agency tucked in two ap­pen­dices. The first was a lengthy guid­ance from June, unedit­ed, on de­vel­op­ment and li­cen­sure of a vac­cine to pre­vent Covid-19. But the sec­ond — a doc­u­ment ti­tled “Sum­ma­ry of Ad­vice Pro­vid­ed to In­di­vid­ual Spon­sors in Re­sponse to Ques­tions Re­gard­ing Emer­gency Use Au­tho­riza­tion of Vac­cines to Pre­vent COVID-19” — is new to the pub­lic.

Per the 5-page sum­ma­ry, the FDA has sug­gest­ed to spon­sors that their EUA re­quests should meet a high­er bar than what’s out­lined in the guid­ance. These ad­di­tion­al safe­ty and ef­fi­ca­cy re­quire­ments match the stricter stan­dards that the FDA was about to pub­lish be­fore the White House over­ruled them.

As­sum­ing com­pa­nies fol­low the ad­vice (and CBER chief Pe­ter Marks has em­pha­sized that they “knew what we’re ex­pect­ing”), it would be all but im­pos­si­ble for any vac­cine de­vel­op­er to sub­mit an up-to-par ap­pli­ca­tion be­fore Elec­tion Day, let alone get cleared for EUA as Pres­i­dent Don­ald Trump has promised.

For in­stance, the FDA said it’s told spon­sors to re­port da­ta with a me­di­an fol­low-up of at least two months af­ter “com­ple­tion of the full vac­ci­na­tion reg­i­men” to mon­i­tor ad­verse events; safe­ty num­bers on “well over 3,000 vac­cine re­cip­i­ents”; and “a to­tal of 5 or more” se­vere Covid-19 cas­es in the place­bo group to as­suage con­cerns about vac­cine-in­duced en­hanced res­pi­ra­to­ry dis­ease.

Then there’s the ad­vice for com­pa­nies to pro­vide a de­tailed de­scrip­tion of their man­u­fac­tur­ing process and con­trols no less than one month pri­or to seek­ing an EUA. That means for an EUA to be is­sued by Nov. 3, a com­pa­ny would have sub­mit­ted this in­for­ma­tion days ago.

Each of these sub­mis­sions, the FDA added, will be scru­ti­nized in­di­vid­u­al­ly by the same pan­el of out­side ex­perts it has con­vened in two weeks:

FDA ex­pects to con­vene an open ses­sion of FDA’s VRB­PAC pri­or to the is­suance of any EUA for a COVID-19 vac­cine, to dis­cuss whether the avail­able safe­ty and ef­fec­tive­ness da­ta sup­port au­tho­riza­tion of an EUA for the spe­cif­ic re­quest un­der re­view. This dis­cus­sion will be spe­cif­ic to the par­tic­u­lar vac­cine that is the sub­ject of the EUA re­quest and will be sep­a­rate from, and in ad­di­tion to, any gen­er­al dis­cus­sion by the VRB­PAC re­gard­ing the de­vel­op­ment, au­tho­riza­tion and/or li­cen­sure of vac­cines to pre­vent COVID-19.

Oct. 22, though, will be when the gen­er­al dis­cus­sion hap­pens. Reg­u­la­tors have asked the ad­comm to ex­plore what ad­di­tion­al stud­ies vac­cine de­vel­op­ers should con­duct, ei­ther be­fore or af­ter an OK, to eval­u­ate their can­di­dates. Should they be do­ing tri­als in chil­dren and preg­nant women? Is there a need for post-mar­ket­ing safe­ty stud­ies fol­low­ing a full BLA ap­proval? What about post-EUA safe­ty fol­low-up?

Pfiz­er/BioN­Tech, Mod­er­na, As­traZeneca/Ox­ford, J&J and a slate of oth­ers will sure­ly be tun­ing in.

For a look at all End­points News coro­n­avirus sto­ries, check out our spe­cial news chan­nel.

MedTech clinical trials require a unique regulatory and study design approach and so engaging a highly experienced CRO to ensure compliance and accurate data across all stages is critical to development milestones.

In­no­v­a­tive MedTech De­mands Spe­cial­ist Clin­i­cal Tri­al Reg­u­la­to­ry Af­fairs and De­sign

Avance Clinical is the Australian CRO for international biotechs providing world-class clinical research services with FDA-accepted data across all phases. With Avance Clinical, biotech companies can leverage Australia’s supportive clinical trials environment which includes no IND requirement plus a 43.5% Government incentive rebate on clinical spend. The CRO has been delivering clinical drug development services for international biotechs for FDA and EMA regulatory approval for the past 24 years. The company has been recognized for the past two consecutive years with the prestigious Frost & Sullivan CRO Best Practices Award and a finalist in Informa Pharma’s Best CRO award for 2022.

FDA commissioner Rob Califf (Tom Williams/CQ Roll Call via AP Images)

With drug pric­ing al­most done, Con­gress looks to wrap up FDA user fee leg­is­la­tion

The Senate won’t return from its summer recess until Sept. 6, but when it does, it officially has 18 business days to finalize the reauthorization of the FDA user fee programs for the next 5 years, or else thousands of drug and biologics reviewers will be laid off and PDUFA dates will vanish in the interim.

FDA commissioner Rob Califf recently sent agency staff a memo explaining how, “Our latest estimates are that we have carryover for PDUFA [Prescription Drug User Fee Act], the user fee funding program that will run out of funding first, to cover only about 5 weeks into the next fiscal year.”

Pascal Soriot, AstraZeneca CEO (David Zorrakino/Europa Press via AP Images)

As­traZeneca and Dai­ichi Sankyo sprint to mar­ket af­ter FDA clears En­her­tu in just two weeks

Regulators didn’t keep AstraZeneca and Daiichi Sankyo waiting long at all for their latest Enhertu approval.

The partners pulled a win on Friday in HER2-low breast cancer patients who’ve already failed on chemotherapy, just two weeks after submitting a supplemental BLA. While this isn’t the FDA’s fastest approval — Bristol Myers Squibb won an OK for its blockbuster checkpoint inhibitor Opdivo in just five days back in March — it comes well ahead of Enhertu’s original Q4 PDUFA date.

Uğur Şahin, BioNTech CEO (Kay Nietfeld/picture-alliance/dpa/AP Images)

De­spite falling Covid-19 sales, BioN­Tech main­tains '22 sales guid­ance

While Pfizer raked in almost $28 billion last quarter, its Covid-19 vaccine partner BioNTech reported a rise in total dose orders but a drop in sales.

The German biotech reported over $3.2 billion in revenue in Q2 on Monday, down from more than $6.7 billion in Q1, in part due to falling Covid sales. While management said last quarter that they anticipated a Covid sales drop — CEO Uğur Şahin said at the time that “the pandemic situation is still very much uncertain” — Q2 sales still missed consensus by 14%.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 147,200+ biopharma pros reading Endpoints daily — and it's free.

Ted Love, Global Blood Therapeutics CEO

Up­dat­ed: Pfiz­er scoops up Glob­al Blood Ther­a­peu­tics and its sick­le cell ther­a­pies for $5.4B

Pfizer is dropping $5.4 billion to acquire Global Blood Therapeutics.

Just ahead of the weekend, word got out that Pfizer was close to clinching a $5 billion buyout — albeit with other potential buyers still at the table. The pharma giant, flush with cash from Covid-19 vaccine sales, apparently got out on top.

The deal immediately swells Pfizer’s previously tiny sickle cell disease portfolio from just a Phase I program to one with an approved drug, Oxbryta, plus a whole pipeline that, if all approved, the company believes could make for a $3 billion franchise at peak.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 147,200+ biopharma pros reading Endpoints daily — and it's free.

David Reese, Amgen R&D chief

UP­DAT­ED: In a fresh dis­ap­point­ment, Am­gen spot­lights a ma­jor safe­ty is­sue with KRAS com­bo

Amgen had hoped that its latest study matching its landmark KRAS G12C drug Lumakras with checkpoint inhibitors would open up its treatment horizons and expand its commercial potential. Instead, the combo spurred safety issues that blunted efficacy and forced the pharma giant to alter course on its treatment strategy, once again disappointing analysts who have been tracking the drug’s faltering sales and limited therapeutic reach.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 147,200+ biopharma pros reading Endpoints daily — and it's free.

GSK and IQVIA launch plat­form of US vac­ci­na­tion da­ta, show­ing drop in adult rates

Throughout the Covid-19 pandemic, the issue of vaccine uptake has been a point of contention, but a new platform from GSK and IQVIA is hoping to shed more light on vaccine data, via new transparency and general awareness.

The two companies have launched Vaccine Track, a platform intended to be used by public health officials, medical professionals and others to strengthen data transparency and display vaccination trends. According to the companies, the platform is intended to aid in increasing vaccine rates and will provide data on trends to assist public health efforts.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 147,200+ biopharma pros reading Endpoints daily — and it's free.

Ab­b­Vie sur­veys emo­tion­al im­pact of chron­ic leukemia con­di­tion, finds 'roller coast­er' of emo­tions

Rare diseases often have more than just physical effects on patients — especially when it comes to chronic conditions. In the case of the rare slow-growing blood cancer chronic lymphocytic leukemia (CLL), AbbVie wanted to try to assess the mental and emotional toll on patients.

So it surveyed more than 300 CLL patients, caregivers and physicians. While each group differed in how they felt — caregivers overwhelmingly (81%) felt positive about their role, for instance — patients described a “roller coaster” of emotions traversing diagnosis to treatment to remission and even relapse for some.

FDA's vac­cine ad­comm to re­view first fe­cal trans­plant to treat C. dif­fi­cile in­fec­tions

Back in 2018, Swiss drugmaker Ferring Pharmaceuticals made a big bet on Minnesota-based Rebiotix, buying up the company for its experimental poop-based drug implant to treat an infection caused by C. difficile, a potentially dangerous bacteria, in a new way.

Four years later, Ferring’s fecal microbiota transplant, dubbed RBX2660 or Rebyota, will face the FDA’s adcomm of outside vaccine experts on Sept. 22, debating whether the agency should license the transplant as a treatment for adults following antibiotic treatment for recurrent C. difficile infection.